Tech Entrepreneur Brian Johnson dubbed “Anti-Aading Millionaire” in a Youtube video, which included a large miscalitation that included a drug that he once believed that his protocol was the cornerstone: Rapamisin. This immunospressant, who was originally developed for organ transplant patients and was now postponed in anti-aging circles, was something that Mr. Johnson had been experimenting for five years.
Inspired by a 2009 study, showing that rapamycin could increase the lifetime of mice up to 14%, as well as 2023 with human testing, where 65% of the participants reported to feel healthy on the drug, Brian Johnson began to fix his dosage properly in the hope of maximum benefits while reducing the risk. But instead of increased vitality, the technical entrepreneur began looking at a series of uncertain side effects.
These included mouth ulcers, delayed wound healing, elevated cholesterol and spikes in blood sugar. Most of the most related to Mr. Johnson had a steady growth in his resting heart rate- a metric that he considers necessary to recover and measure the quality of sleep. Physical red flags inspired him to rethink rapamycin in his anti-aging protocol.
Watch youtube video here:
His suspicion was recently reinforced by a study by the University of Yale, which directly challenged the positive story around the rapamycin. Unlike its reputation, the study suggested that the drug can actually accelerate biological aging. Researchers identify 16 adverse effects on epigenetic marker-biological indicators, which are tied with age-increase serious concerns about long-term use of the drug as an increase in longevity.
For Mr. Johnson, the conclusion was a major blow. Once the foundation stone of his health adaptation scheme was now seen to work against him. In his YouTube video, he admitted to irony with a sense of humility: “For those of you who are laughing at home, I am laughing with you,” he said, unwanted by revelation.
Although he confirmed that he has stopped taking rapamycin, Mr. Johnson insisted that it is not a defeat, but a strategic axis. “This is not the end-it’s a reset,” he said. “It is important to share both victory and failures. This is how progressed.”
